Margaret Kaczor: Yes. That was great. And then, I guess, turning further on that right, so the existing accounts who already have a good sense of training and patient use and history with Barostim. Have you talked to them about what their expectations are for the trial and how they might change their utilization once the data is now I’ll also make one more and walk us through how they would view their TAM opportunity changing? Should one of those more positive scenarios come up?
Nadim Yared: question and now I wonder if I should have spoken with some physicians about this, number one, we instruct our sales force to be super careful and stick up with the FDA approved labeling. So that’s why they do not engage in speculative discussions regarding outcome. However, I could do that as explore that kind of getting feedbacks perspective. That said, there is one area where our TAM will increase even if we hit the endpoint. When we negotiated as the current labeling with FDA back in 2019. FDA was very clear that we have not met yet the more customer base, because it was not what we outlined it for. And PRC devices when they are a Class 1 indicated, so QRS about 150 and the presence of a left bundle , they have a and more talking about modality benefit.
FDA did not want physicians to prescribe auto device itself. In those situations. So that’s why in our calculation of the total addressable market, we excluded patients who are eligible actually indicated for a CRT treatment. I believe that if we hit, endpoint, I know that we will ask FDA to remove that exclusion and I believe that FDA will accept exclusion, because we should then let the physician decide what therapy is more appropriate for their patients and the labeling would allow us than for those patients who are indicated for a CRT device. So that will increase the total addressable market. we have to expand of how much Margaret, but at the right time, probably during the discussion about the results, we — I’m speculating here, but I believe we’ll be ready with the updated numbers of the total addressable market at the same time.
So in Q1.
Margaret Kaczor: Great. Thanks. That’d be fantastic. Thanks guys.
Nadim Yared: Thank you.
Operator: Thank you. One moment for our next question. That will come from the line of William Plovanic with Canaccord. Your line is open.
William Plovanic: Great. Thanks. Good evening. Thanks for taking my questions. A lot of them have already been answered, so I think I’ll stick with some guidance and P&L stuff. As you talked, you gave us the rep cadence you expect in terms of the new account cadence. Would you expect that to stay the same or are you shifting more to a go deep strategy?
Jared Oasheim: Hey, Bill, this is Jared. I can handle that one. So from an account perspective, last year, we were talking about adding high single-digits on a quarterly basis throughout 2022. This year, we’re expecting that to be in the range of about 10 to 12 new active implanting centers added on a quarterly basis as we march through 2023. And then there is going to be a bit of work done by the account managers to really start digging a little bit deeper and work in the referral pathway for those centers that are already active. So the centers that have been around for 12 or 24 months trying to go a little bit deeper, reach out to more of the referral cardiologists along the way.
William Plovanic: Okay. And that kind of that ties into the DTC question and I think you kind of alluded to the fact that I want to make sure I heard that right is, is this more of a efficiency in terms of spend that you’re trying to titrate and find out what is the most efficient in terms of getting a patient and converting them or getting a lead and converting it through a patient. Is that where a lot of the focus on the DTC is today?